 CytoDyn Inc, a late-stage biotechnology company developing its flagship drug leronlimab for multiple indications, has revealed the publication of a peer-reviewed research paper on the suppression of human and simian immunodeficiency virus replication with the help of leronlimab. The research paper titled Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species was published in the open-access PLOS Pathogens journal. 